Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 7/20 | 0.43 |
| ▸ | ITPR2 | Q14571 | 3/20 | 0.42 |
| ▸ | ITPR1 | Q14643 | 3/20 | 0.42 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.40 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.38 |
| ▸ | PPIP5K2 | O43314 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3073513 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6389556 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL3078845 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL15134078 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL5667749 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8845346 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6388024 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8498941 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL8844497 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 | |
| SCHEMBL6393461 | 1.00 | ITPR3 (0.43) | ITPR3ITPR2ITPR1INPPL1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7453006-B2 | Inositol derivatives for increasing chloride secretion and inhibiting inflammation | INOLOGIC, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1435969-A4 | METHOD OF MODULATING SODIUM ION ABSORPTION IN EPITHELIAL CELLS | INOLOGIC INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050020542-A1 | Method of modulating sodium ion absorption in epithelial cells | INOLOGIC, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040147487-A1 | Inositol derivatives for increasing chloride secretion and inhibiting inflammation | INOLOGIC, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1435969-A2 | METHOD OF MODULATING SODIUM ION ABSORPTION IN EPITHELIAL CELLS | Inologic, Inc. (US) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003024189-A2 | METHOD OF MODULATING SODIUM ION ABSORPTION IN EPITHELIAL CELLS | INOLOGIC, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147487-A1 | Inositol derivatives for increasing chloride secretion and inhibiting inflammation | PPIP5K2, ITPR2, ITPR3 | ITPR3 3/4885ITPR2 2/4885ITPR1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.